Abstract:Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas. ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997. Physiological ALK participates in embryonic nervous system development, but its expression decreases after birth. ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase. Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors. The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers. The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process. Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway. Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression. The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors. Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-positive non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease. The emergence of crizotinib drug resistance with a median occurrence at approximately 10 months after the initiation of therapy has stimulated the development of second-generation drugs for the treatment of non-small cell lung cancer and other disorders. About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms. It is remarkable that the EML4-ALK fusion protein was discovered in 2007 and crizotinib was approved for the treatment of ALK-positive non-small cell lung cancer in 2011, which is a remarkably short timeframe in the overall scheme of drug discovery.

The Orphan Receptor Serine/Threonine Kinase ALK7 Signals Arrest of Proliferation and Morphological Differentiation in a Neuronal Cell Line

Cdna Cloning, Expression Studies and Chromosome Mapping of Human Type I Serine/threonine Kinase Receptor ALK7 (ACVR1C)

The Orphan Receptor ALK7 and the Activin Receptor ALK4 Mediate Signaling by Nodal Proteins During Vertebrate Development.

A novel type I receptor serine-threonine kinase predominantly expressed in the adult central nervous system.

Activin Receptor-like Kinase (ALK)1 is an Antagonistic Mediator of Lateral TGFβ/ALK5 Signaling

Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition

Overexpression of Activin Receptor-like Kinase 7 in Breast Cancer Cells is Associated with Decreased Cell Growth and Adhesion.

Phosphoproteomic Analysis of Anaplastic Lymphoma Kinase (alk) Downstream Signaling Pathways Identifies Signal Transducer and Activator of Transcription 3 As A Functional Target of Activated Alk in Neuroblastoma Cells

Smad7 And Protein Phosphatase 1 Alpha Are Critical Determinants In The Duration Of Tgf-Beta/Alki Signaling In Endothelial Cells

ALK7 Protects Against Pathological Cardiac Hypertrophy in Mice

Smad7 and Protein Phosphatase 1α Are Critical Determinants in the Duration of TGF-β/ALK1 Signaling in Endothelial Cells

Alk7, A Receptor for Nodal, is Dispensable for Embryogenesis and Left-Right Patterning in the Mouse

Remodeling Retinal Neovascularization by ALK1 Gene Transfection in Vitro.

Activin Receptor-Like Kinase 1 Modulates Transforming Growth Factor-Beta 1 Signaling in the Regulation of Angiogenesis.

ALK1 Opposes ALK5/Smad3 Signaling and Expression of Extracellular Matrix Components in Human Chondrocytes

TGF-β Type I Receptor/alk-5 and Smad Proteins Mediate Epithelial to Mesenchymal Transdifferentiation in NMuMG Breast Epithelial Cells

Signaling Via Alk5 Controls the Ontogeny of Lung Clara Cells

Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression

Anti-Human Activin Receptor-Like Kinase 1 (alk1) Antibody Attenuates Bone Morphogenetic Protein 9 (Bmp9)-Induced Alk1 Signaling and Interferes with Endothelial Cell Sprouting

Constitutive Activation of Activin Receptor-like Kinase 2 in Human Breast Cancer Cells inhibits Metastatic Progression and Osteolytic Bone Lesions

Nerve growth factor induces survival and differentiation through two distinct signaling cascades in PC12 cells